GTx,Inc. (NASDAQ:GTXI) Files An 8-K Other Events

GTx,Inc. (NASDAQ:GTXI) Files An 8-K Other Events
Item 8.01 Other Events

Story continues below

On May16, 2018, GTx,Inc. (the “Company”) sold 1,501,501 shares of its common stock for gross proceeds of approximately $25.0million. The shares were sold to the At-the-Market Equity Offering Sales Agreement (the “Sales Agreement”) with Stifel, Nicolaus& Company,Incorporated (“Stifel”), dated February9, 2018. Following these sales, the Company may offer and sell additional shares of its common stock having an aggregate offering price of up to $25.0million from time to time through Stifel to the sales agreement.

About GTx,Inc. (NASDAQ:GTXI)

GTx, Inc. is a biopharmaceutical company focused on the discovery, development and commercialization of small molecules for the treatment of cancer, including treatments for breast and prostate cancer, and other medical conditions. The Company is engaged in the development of selective androgen receptor modulators (SARMs). Its lead product candidate, enobosarm (GTx-024), had been evaluated in over 24 completed or ongoing clinical trials, including in approximately six Phase II and two Phase III clinical trials. The Company is also engaged in the development of GTx-758 (Capesaris), an oral nonsteroidal selective estrogen receptor alpha agonist, for secondary hormonal therapy in men with metastatic and high-risk non-metastatic castration resistant prostate cancer (CRPC). Its product candidate, Enobosarm, for the treatment of women with advanced androgen receptor (AR) positive triple-negative breast cancer (TNBC), is in Phase II clinical development-stage.

An ad to help with our costs